Sale

Primary Hyperoxaluria Treatment Market

Global Primary Hyperoxaluria Treatment Market Share, Size, Analysis, Forecast: By Type: Primary Hyperoxaluria Type I, Others; By Diagnosis Method: Urine Tests, Blood Tests, Stone Analysis, DNA Testing, Kidney Biopsy, Echocardiogram, Others; By Treatment Method; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Primary Hyperoxaluria Treatment Market Outlook

The global primary hyperoxaluria treatment market size reached a value of about USD 18.91 million in 2023 and is expected to grow at a CAGR of 3.7% during the forecast period of 2024-2032. With the growing awareness of rare disease and genetic engineering advancement, the market is expected to reach a value of about USD 26.16 million by 2032.

 

primary hyperoxaluria treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Primary Hyperoxaluria Insights

Primary hyperoxaluria (PH) is a rare genetic disease caused by glyoxylate metabolism deficiencies. The PH is autosomal recessive and is classified into three types based on the responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). The kidney is the primary site of oxalate deposition, which in many cases leads to end-stage renal disease.

 

End stage renal disease (ESRD) is a life-threatening condition that prevents the kidneys from effectively filtering fluids and waste products from the body.

 

Kidney stones in primary hyperoxaluria type 1 typically appear between childhood and early adulthood, and ESRD can develop at any age. The symptoms of primary hyperoxaluria type 2 are similar to those of type 1, but ESRD develops later in life. Primary hyperoxaluria type 3 patients frequently develop kidney stones in childhood, but few cases of this type have been described, so additional signs and symptoms are unknown.

 

Recurrent kidney stones, hematuria, and urinary tract infections (UTIs) are possible signs and symptoms. If left untreated, PH-I can progress to end-stage renal disease, which can be fatal. The disease is characterised phenotypically by the recurrent formation of kidney stones and nephrocalcinosis, which results in the gradual decline of kidney function. When renal function deteriorates, excess oxalate cannot be eliminated through the urine, and calcium oxalate crystals precipitate in various tissues, resulting in systemic oxalosis, a devastating multiorgan disease.

 

Changes (mutations) in the AGXT gene cause PH type I. Mutations in the GRHPR gene cause PH type II. Mutations in the HOGA1 gene cause PH type III. Genes encode instructions for the production of proteins, which are essential for many bodily functions. When a gene is mutated, the protein product may be faulty, inefficient, or absent. Depending on the functions of the specific protein, this can have an impact on many organ systems in the body.

 

According to the market research report, the primary hyperoxaluria treatment market can be categorised into the following segments:

 

primary hyperoxaluria treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Primary Hyperoxaluria Type I
  • Primary Hyperoxaluria Type II
  • Primary Hyperoxaluria Type II

 

Market Breakup by Diagnosis Method

  • Urine Tests
  • Blood Tests
  • Stone Analysis
  • Kidney X-rays, Ultrasound or Computerized Tomography (CT) Scan
  • DNA Testing
  • Kidney Biopsy
  • Echocardiogram
  • Eye Exam
  • Bone Marrow Biopsy
  • Liver Biopsy

 

Market Breakup by Treatment Method

  • Medications
    • Potassium Citrate
    • Thiazide Diuretics
    • Vitamin Supplements
    • Lumasiran
  • High Fluid Intake
  • Dietary Changes
  • Kidney Stone Management
  • Dialysis and Transplantation

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

primary hyperoxaluria treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Primary Hyperoxaluria Epidemiology

Males and females are equally affected by PH. These disorder’s exact incidence and prevalence are unknown. Because some cases go undiagnosed or are misdiagnosed, it is difficult to determine the true prevalence of these conditions in the general population. Young patients with recurring kidney stone formation may benefit from molecular genetic testing. However, some patients with common PH symptoms are not found to have the known genetic mutations linked to PH, implying that the true number of people with PH is likely to be underestimated. The most common form is PH type I. 

 

According to one estimate, the prevalence of PH type I in the general population is 1-3 cases per 1,000,000 people, with fewer than 1,000 people affected in the United States, and the incidence is 1 case per 120,000 live births per year in Europe. PH is estimated to be 2.5 times more common in European Americans than in African Americans.

 

Global Primary Hyperoxaluria Treatment Market Drivers and Restraints

The population growing awareness of rare and genetic disorders is expected to drive the demand for primary hyperoxaluria treatment. During the forecast period, technological advancements in the field of genetic engineering will drive the demand for global primary hyperoxaluria treatment market.

 

The number of leading pharmaceutical companies with products in clinical trials for the treatment of primary hyperoxaluria will drive the market growth. In the coming decade, demand for primary hyperoxaluria treatment will rise due to an increase in diagnosis and treatment seeking. Global primary hyperoxaluria treatment market growth is hampered by a small patient population available for clinical trials.

 

Global Primary Hyperoxaluria Therapeutic Landscape

Treatment is determined by the type, symptoms, and severity of hyperoxaluria, and by how well the patient responds to the treatment.

 

Treatment may necessitate the collaborative efforts of a team of specialists. Pediatricians, surgeons, specialists who assess and treat kidney problems (nephrologists), specialists who assess and treat liver problems (hepatologists), specialists who assess and treat urinary tract problems (urologists), dieticians, and other healthcare professionals may need to plan an affected child's treatment systematically and comprehensively. Genetic counselling is advised to assist families in understanding the genetics and natural history of PH, and to provide psychosocial support. 

 

Lumasiran (Oxlumo) is a medication that reduces oxalate production in children and adults with primary hyperoxaluria. In some people with primary hyperoxaluria, prescription doses of vitamin B-6 can help reduce oxalate in the urine. Phosphate and citrate oral preparations aid in the prevention of calcium oxalate crystal formation. Depending on the other abnormalities in the urine, other medications, such as thiazide diuretics, may be considered.

 

Global Primary Hyperoxaluria Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global primary hyperoxaluria treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

 

  • Alnylam Pharmaceuticals
  • Tecoland Corporation
  • Zhejiang Tianxin Pharmaceuticals Co.
  • Takeda Pharmaceuticals
  • Wuxi Further Pharmaceutical Co Ltd
  • Genentech
  • OxThera
  • Dicerna Pharmaceuticals, Inc.
  • Allena Pharmaceuticals

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Diagnosis Method
  • Treatment Method
  • Treatment Channel
  • Region
Breakup by Type
  • Primary Hyperoxaluria Type I
  • Primary Hyperoxaluria Type II
  • Primary Hyperoxaluria Type III
Breakup by Diagnosis Method
  • Urine Tests
  • Blood Tests
  • Stone Analysis
  • Kidney X-ray, Ultrasound or Computerized Tomography (CT) Scan
  • DNA Testing
  • Kidney Biopsy
  • Echocardiogram
  • Eye Exam
  • Bone Marrow Biopsy
  • Liver Biopsy
Breakup by Treatment Method
  • Medications
  • High Fluid Intake
  • Dietary Changes
  • Kidney Stone Management
  • Dialysis and Transplantation
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model
  • Key Demand Indicators 
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Alnylam Pharmaceuticals, Inc.
  • Tecoland Corporation
  • Zhejiang Tianxin Pharmaceutical Co.
  • Takeda Pharmaceuticals
  • Wuxi Further Pharmaceutical Co Ltd
  • Genentech
  • OxThera
  • Dicerna Pharmaceuticals, Inc.
  • Allena Pharmaceuticals

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Primary Hyperoxaluria Overview 

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview 
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials 
    6.2    Patent Landscape
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop- out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Primary Hyperoxaluria Treatment Market  
    8.1    Global Primary Hyperoxaluria Treatment Market Overview
    8.2    Global Primary Hyperoxaluria Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Historical Primary Hyperoxaluria Market Value (2017-2023) 
            8.2.1.2    Global Forecast Primary Hyperoxaluria Market Value (2024-2032)
        8.2.2    Global Primary Hyperoxaluria Treatment Market by Type
            8.2.2.1    Market Overview
                8.2.2.1.1    Primary Hyperoxaluria Type I
                8.2.2.1.2    Primary Hyperoxaluria Type II
                8.2.2.1.3    Primary Hyperoxaluria Type III
        8.2.3    Global Primary Hyperoxaluria Treatment Market by Diagnosis Method  
            8.2.3.1    Market Overview
                8.2.3.1.1    Urine Tests
                8.2.3.1.2    Blood Tests
                8.2.3.1.3    Stone Analysis
                8.2.3.1.4    Kidney X-ray, Ultrasound or Computerized Tomography (CT) Scan
                8.2.3.1.5    DNA Testing
                8.2.3.1.6    Kidney Biopsy
                8.2.3.1.7    Echocardiogram
                8.2.3.1.8    Eye Exam
                8.2.3.1.9    Bone Marrow Biopsy
                8.2.3.1.10    Liver Biopsy
        8.2.4    Global Primary Hyperoxaluria Treatment Market by Treatment Method
            8.2.4.1    Market Overview
                8.2.4.1.1    Medications
                    8.2.4.1.1.1    Potassium Citrate
                    8.2.4.1.1.2    Thiazide Diuretics
                    8.2.4.1.1.3    Vitamin Supplements
                    8.2.4.1.1.4    Lumasiran
                8.2.4.1.2    High Fluid Intake
                8.2.4.1.3    Dietary Changes
                8.2.4.1.4    Kidney Stone Management
                8.2.4.1.5    Dialysis and Transplantation
        8.2.5    Global Primary Hyperoxaluria Treatment Market by Treatment Channel
            8.2.5.1    Market Overview
                8.2.5.1.1    Public
                8.2.5.1.2    Private
        8.2.6    Global Primary Hyperoxaluria Treatment Market by Region
            8.2.6.1    Market Overview
                8.2.6.1.1    North America
                8.2.6.1.2    Europe 
                8.2.6.1.3    Asia Pacific
                8.2.6.1.4    Latin America
                8.2.6.1.5    Middle East and Africa
9    North America  Primary Hyperoxaluria Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Primary Hyperoxaluria Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Primary Hyperoxaluria Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Primary Hyperoxaluria Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Primary Hyperoxaluria Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Primary Hyperoxaluria Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators
    14.6    Industry Events, Initiatives, and Trends  
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Alnylam Pharmaceuticals, Inc. 
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Tecoland Corporation 
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Zhejiang Tianxin Pharmaceutical Co. 
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Takeda Pharmaceuticals 
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Wuxi Further Pharmaceutical Co Ltd 
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Genentech
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    OxThera
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Dicerna Pharmaceuticals, Inc.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Allena Pharmaceuticals
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
16    Primary Hyperoxaluria Treatment Market- Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 18.91 million in 2023, driven by the growing awareness of rare disease and genetic engineering advancement.

The market is expected to rise at a CAGR of 3.7% during the forecast period of 2024-2032 to attain a value of USD 26.16 million by 2032.

The increased awareness of rare diseases and advancement in the genetic engineering is a critical factor driving the market growth.

Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceuticals Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals among others are the leading companies in the market.

Small population available for the clinical trials will restrain the growth of the market.

Primary hyperroxaluria has no known cure. The goal is to protect the kidneys by preventing the formation of kidney stones and the formation and deposit of calcium oxalate in other body tissues.

Lumasiran (Oxlumo) is a medication that reduces oxalate production in children and adults with primary hyperoxaluria. In some people with primary hyperoxaluria, prescription doses of vitamin B-6 can help reduce oxalate in the urine.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER